The company had posted net profit of Rs 128.6 crore in the same quarter of the previous year.
Consolidated net sales of the company rose by 19.38 per cent to Rs 1,477.8 crore during the quarter under review, as against Rs 1,237.8 crore in the same period of previous fiscal, Glenmark Pharma said in a BSE filing.
"We have delivered strong results backed by good performances by our India, Rest of the World, Europe and LATAM (Latin America) businesses. While we outperformed in the Indian Pharmaceutical market with a growth of over 20 per cent," company's Chairman and MD Glenn Saldanha said.
"We have been making steady progress in our innovation pipeline and now have three first-in-class monoclonal antibodies in clinical development," he added.
The company's India business grew by 20.87 per cent to Rs 397.1 crore while US business grew by 9.33 per cent to Rs 488.6 crore.
Its rest of the world (ROW) business grew by 20.67 per cent to Rs 211.3 crore.
Glenmark scrip closed at Rs 596.25, up 0.78 per cent from its previous close on the BSE.